Your browser doesn't support javascript.
loading
JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.
Barosi, G; Klersy, C; Villani, L; Bonetti, E; Catarsi, P; Poletto, V; Campanelli, R; Impera, S; Latagliata, R; Viarengo, G; Carolei, A; Massa, M; Musso, M; Crescimanno, A; Gale, R P; Rosti, V.
Afiliação
  • Barosi G; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Klersy C; Biometry and Clinical Epidemiology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Villani L; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Bonetti E; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Catarsi P; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Poletto V; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Campanelli R; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Impera S; Hematology, Presidio Ospedaliero Garibaldi-Nesima, Catania, Italy.
  • Latagliata R; Department of Cellular Biotechnology and Hematology, University of Rome, La Sapienza, Italy.
  • Viarengo G; Immunohematology and Transfusion Service, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Carolei A; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Massa M; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  • Musso M; Dipartimento Oncologico 'La Maddalena', UO di Oncologia e Trapianto di Midollo, Palermo, Italy.
  • Crescimanno A; Dipartimento Oncologico 'La Maddalena', UO di Oncologia e Trapianto di Midollo, Palermo, Italy.
  • Gale RP; Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
  • Rosti V; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Leukemia ; 30(8): 1772-5, 2016 08.
Article em En | MEDLINE | ID: mdl-26975727
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Esplenomegalia / Janus Quinase 2 / Mielofibrose Primária / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Esplenomegalia / Janus Quinase 2 / Mielofibrose Primária / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália